LaNeo MDMA

Business news, market intelligence, and global industry analysis.

The Latest

Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Stability data and strategy: PharmAla Biotech Holdings Inc. builds commercial groundwork for LaNeo MDMA

PharmAla Biotech Holdings Inc. launches a three-year stability program for LaNeo MDMA. Discover how this could reshape psychedelic drug commercialization.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

February 26, 2026